Pathology

Nodexus Adds Flow Cytometry Leaders to Scientific Advisory Board

Retrieved on: 
Mercoledì, Aprile 10, 2024
Oncology, Health, Health Technology, Research, Science, Pharmaceutical, Biotechnology, Breast cancer, Science Publishing Group, Immortalised cell line, University, International Society, ISAC, Jonni, SAB, CRISPR, Cell biology, Hospital, Seminal vesicles, Medical laboratory, Doctor of Philosophy, Pathology, Protein engineering, Therapy, New York Blood Center, Chairperson, Synthetic biology, Cardiovascular disease, Malignancy, Assistant, Inc., NX, HIV, Biomarker, Associate, SICS, AAPS, Flow cytometry

Nodexus Inc., a leader in automated benchtop single-cell characterization and microfluidic isolation technologies, today announced that three leading experts in cytometry sciences, pathology, and cancer biology have joined its Scientific Advisory Board (SAB).

Key Points: 
  • Nodexus Inc., a leader in automated benchtop single-cell characterization and microfluidic isolation technologies, today announced that three leading experts in cytometry sciences, pathology, and cancer biology have joined its Scientific Advisory Board (SAB).
  • The Nodexus SAB is chaired by Professor Jonni Moore, PhD, one of the world’s leading experts in flow cytometry, laboratory medicine, and cellular immunology.
  • He is a founding member of the Southern California Flow Cytometry Association (SoCal Flow) and the American Association of Pharmaceutical Scientists (AAPS) PharmaFlow Working Group.
  • “I’m extremely pleased to serve as the Chairperson of Nodexus’ Scientific Advisory Board,” said Dr. Moore.

German Gynecological Oncology Group (AGO) Recognizes BluePrint® in Breast Cancer Guidelines

Retrieved on: 
Giovedì, Aprile 11, 2024
Research, Medical Devices, Hospitals, FDA, Genetics, Radiology, Health, Science, Oncology, Other Science, Blueprint, Woman, AGO, Breast, MD, Doctor of Philosophy, Pathology, Clinic, Gynaecology, Patient, Physician, Diagnosis, Standard of care, Radiation, Neoplasm, Breast cancer, Medical imaging

Agendia®, Inc. announced today that the company’s 80-gene molecular subtyping assay, BluePrint®, is now included in the latest version of German Gynecological Oncology Group (AGO) guidelines.

Key Points: 
  • Agendia®, Inc. announced today that the company’s 80-gene molecular subtyping assay, BluePrint®, is now included in the latest version of German Gynecological Oncology Group (AGO) guidelines.
  • Agendia’s MammaPrint® was added to the AGO guidelines in 2017, with level 1B medical evidence for identification of patient subgroups who can potentially forgo chemotherapy for breast cancer.
  • MammaPrint was also added to the list of prognostic and predictive factors for extended endocrine therapy in the 2023 AGO guidelines.
  • AGO is a joint expert group consisting of gynecological oncologists specialized in breast cancer and interdisciplinary members specialized in pathology, radiologic diagnostics, medical oncology and radiation oncology.

Dr. J. Mark Tuthill Joins Gestalt Diagnostics' Strategic Advisory Board

Retrieved on: 
Venerdì, Aprile 26, 2024
Education, Science Publishing Group, Informatics, Henry Ford Health, Learning, Advisory board, Medical laboratory, Research, Pathology, API, Digital, Marie Cassidy, Computer, Patient, Henry Ford

SPOKANE, Wash., April 26, 2024 /PRNewswire/ -- Gestalt Diagnostics has added healthcare industry expert, Dr. J. Mark Tuthill, to serve on Gestalt's Advisory Board. He will be joining Gestalt's distinguished Advisory Board of pathologists contributing to oversight and active input of development initiatives as they relate to the functionality and usability of solutions in clinical practice, education, and research.

Key Points: 
  • Gestalt's Advisory Board guides the development of Gestalt's digital pathology platform, PathFlow® – made by pathologists for pathologists
    SPOKANE, Wash., April 26, 2024 /PRNewswire/ -- Gestalt Diagnostics has added healthcare industry expert, Dr. J.
  • Mark Tuthill, to serve on Gestalt's Advisory Board.
  • Dr. Tuthill is the Division Head of Pathology Informatics and Pathology Informatics Fellowship Director at Henry Ford Health where his specialties include both pathology and clinical informatics.
  • Dr. Tuthill states, "I am honored to be invited to serve on the Gestalt Strategic Advisory Board.

Gordian Biotechnology Introduces High-Throughput In Vivo Screening Platform to Discover Therapies and Better Predict Human Outcomes for Age-Related Diseases

Retrieved on: 
Venerdì, Aprile 26, 2024
Founders Fund, FDA, OA, Patient, Horse, Cell, Notifiable disease, Animal, OARSI, Osteoarthritis Research Society International, Infection, Entrepreneurship, Research, Pathology, Artificial intelligence, Disease, Human, Novartis, Therapy, Ageing, Pulmonary fibrosis, Osteoarthritis, Gene, Biology, Drug discovery, Longevity, World Congress, MASH, Heart failure, Pharmaceutical industry

SAN FRANCISCO, April 26, 2024 /PRNewswire/ -- Gordian Biotechnology, an in vivo drug discovery and development company, today announced its platform that enables patient predictive, in vivo screening of hundreds of gene targets for FDA-recognized diseases of aging at a scale never before possible.

Key Points: 
  • Gordian's Osteoarthritis (OA) program has screened hundreds of therapies in horses that acquired OA naturally and advanced dozens of therapies into human ex vivo validation studies.
  • In proof of concept experiments during initial development, Gordian introduced a pooled library of 50 gene therapies into a mouse model of metabolic-associated steatohepatitis (MASH).
  • The therapies were evaluated using the company's proprietary in vivo screening platform, which successfully recapitulated 13 out of 16 clinical outcomes for targets where clinical data exists.
  • Mosaic Screening™ is pooled in vivo screening that tests hundreds of therapies simultaneously in a single sick animal, the Patient Avatar.

Hoag Family Cancer Institute Welcomes Oncology 'Power Couple'

Retrieved on: 
Giovedì, Aprile 25, 2024
Cloud, Circle, Cancer, University, D.S, Hospital, Drug development, Hematology, Immunotherapy, Oncology, Research, Pathology, University of Texas System, Cedars-Sinai Medical Center, Patient, Medicine, Lung, Breast cancer, Nursing

NEWPORT BEACH, Calif., April 25, 2024 /PRNewswire/ -- Hoag is proud to announce the recruitment of cancer researchers and subspecialized oncologists Monica Mita, M.D., M.Sc., Mh.D.S., and Alain Mita, M.D., M.Sc., to the Hoag Family Cancer Institute.

Key Points: 
  • Husband and wife team Alain Mita, M.D., and Monica Mita, M.D., join Hoag from Cedars-Sinai Medical Center as new program directors
    NEWPORT BEACH, Calif., April 25, 2024 /PRNewswire/ -- Hoag is proud to announce the recruitment of cancer researchers and subspecialized oncologists Monica Mita, M.D., M.Sc., Mh.D.S., and Alain Mita, M.D., M.Sc., to the Hoag Family Cancer Institute.
  • Dr. Monica Mita joins Hoag as co-director of early phase development therapy and co-director of breast medical oncology.
  • These advanced treatments offered at the Hoag Family Cancer Institute are usually only available at large academic cancer centers, which makes Hoag so unique."
  • He also completed an advanced oncology drug development fellowship program at the Institute for Drug Development at the Cancer Therapy and Research Center and University of Texas Health Science Center.

NashBio and CuriMeta Collaborate to Expand and Diversify Advanced Real-World Health Datasets

Retrieved on: 
Giovedì, Aprile 25, 2024
Genomics, AUC, Vanderbilt University, EMR, Research, Pathology, Disease, Radiology, DNA, Therapy, Science, RWD, Medicine, Vanderbilt University Medical Center, Organization, Pharmaceutical industry

ST. LOUIS, April 25, 2024 /PRNewswire/ -- CuriMeta, a leading expert in life science-focused, advanced real-world health data, and NashBio, a leading real-world, multi-omics data company, today announced a data licensing agreement that will bring together each organizations' distinct expertise in real-world data (RWD).

Key Points: 
  • NashBio provides real-world clinical, genomic and imaging data to their healthcare and life science research partners through their biobank, BioVU®.
  • This advanced RWD helps advance novel discoveries and the development of new, more personalized therapeutics and diagnostics.
  • "At NashBio, we say smarter data is in our DNA", said Leeland Ekstrom, founder and CEO, NashBio.
  • "Strategic collaborations with organizations like CuriMeta enhance our datasets and biobank, bringing broader, more diverse datasets to our clients.

CHOP Researchers Discover Underlying Biology Behind Fontan-Associated Liver Disease

Retrieved on: 
Mercoledì, Aprile 24, 2024
Online, Science Publishing Group, Fontan procedure, Patient, Cell, Hepatocyte, Liver disease, Inferior vena cava, Science Translational Medicine, Hope, NIH, Hospital, Blood, Tissue, Robert, CHOP, Agent handling, Heart, Wellness, MD, RNA, Medical laboratory, Doctor of Philosophy, SVRF, Activity, Survivor, Disease, Pathology, Ventricular septal defect, Fibrosis, Stasi, FC, Assistant, Biology, Children's Hospital of Philadelphia, Quality of life, Scar, Defense, Pharmaceutical industry

PHILADELPHIA, April 24, 2024 /PRNewswire/ -- As patients with congenital heart diseases live longer, researchers are attempting to understand some of the other complications they may face as they age. In a new study, a team from Children's Hospital of Philadelphia (CHOP) used state-of-the-art technologies to understand the underlying biology of Fontan-associated liver disease (FALD).

Key Points: 
  • In a new study, a team from Children's Hospital of Philadelphia (CHOP) used state-of-the-art technologies to understand the underlying biology of Fontan-associated liver disease (FALD).
  • The Fontan operation is the current standard of care for single-ventricle congenital heart disease.
  • As more patients undergo the Fontan surgery for single-ventricle congenital heart disease, FALD has become a more recognized problem.
  • Little information exists on FALD, yet it is distinct from other forms of liver disease, which is why researchers at CHOP wanted to understand the basic biology that could lead to better treatment options and improve these patients' quality of life.

University of Medicine and Health Sciences Celebrates Historic Match Day for Graduating Students

Retrieved on: 
Lunedì, Aprile 22, 2024
Blog, University, Spectrum Health, Learning, Psychiatry, Emergency medicine, Dream, Anesthesiology, Internal medicine, Pediatrics, Pathology, History, UMHS, Obstetrics, Patient, Neurology, Child, Rehabilitation, Student, Detroit Medical Center, General surgery, Case Western Reserve University, COVID-19, Interventional radiology, Nursing

NEW YORK, April 22, 2024 /PRNewswire-PRWeb/ -- The University of Medicine and Health Sciences, (UMHS), a small, mission-driven medical school with a commitment to student support and a legacy of successful residency placements in the United States and Canada, celebrated one of its most successful Match Days in history. A remarkable 91% of first-time applicants secured residency placements, with graduating students earning positions in competitive programs across 14 medical specialties spanning 27 states, Puerto Rico, and Canada.

Key Points: 
  • In a message to students, UMHS President Warren Ross praised the school's historic 2024 Match results.
  • Graduating students secured residencies in highly competitive programs and will continue their training at esteemed teaching hospitals such as Case Western in Ohio and the University of Massachusetts Chan Medical School.
  • UMHS students matched into all six core specialties, including family medicine, internal medicine, obstetrics & gynecology, pediatrics, psychiatry, and surgery, as well as eight specialty fields, including anesthesiology, child neurology, diagnostic radiology, emergency medicine, neurology, pathology, and physical medicine and rehabilitation.
  • To learn more about the UMHS Class of 2024 Match Day and to see the complete 2024 Match results please visit https://www.umhs-sk.org/match-results .

Announcing the Accreditation of Anderson College's Medical Office Administrator Program

Retrieved on: 
Venerdì, Aprile 19, 2024
Medicine, NCE, Electronic health record, EMR, Quality assurance, Pathology, Student, Business, History, Curriculum, Office management, Anderson University, Accreditation, MOA, Workforce, Health information management, Knowledge, Nursing

TORONTO, April 19, 2024 /CNW/ - Anderson College of Health, Business and Technology is proud to announce that its Medical Office Administrator program has received accreditation status from The Canadian College of Health Information Management (CCHIM).

Key Points: 
  • TORONTO, April 19, 2024 /CNW/ - Anderson College of Health, Business and Technology is proud to announce that its Medical Office Administrator program has received accreditation status from The Canadian College of Health Information Management (CCHIM).
  • Announcing the Accreditation of Anderson College's Medical Office Administrator Program.
  • "Our college is proud to announce the accreditation of the Medical Office Administrator Program offered by Anderson College," states Jeff Nesbitt, CEO & Registrar of the CCHIM.
  • Students can learn more by visiting Anderson College's Medical Office Administrator program .

AIxMed and CorePlus Partner to study a Urine Cytology Workflow Solution

Retrieved on: 
Giovedì, Aprile 18, 2024
Workforce, Workflow, Cell, Bladder cancer, Pathology, Research, AI, Medical device

SANTA CLARA, Calif. , April 18, 2024 /PRNewswire/ -- AIxMed, innovators and providers of an AI-powered computational platform for cytology applications, and CorePlus a leader in precision pathology have entered into an agreement to conduct a pilot study applying the AIxMed's AI algorithm to test a workflow solution for urine cytology.

Key Points: 
  • SANTA CLARA, Calif. , April 18, 2024 /PRNewswire/ -- AIxMed , innovators and providers of an AI-powered computational platform for cytology applications, and CorePlus a leader in precision pathology have entered into an agreement to conduct a pilot study applying the AIxMed's AI algorithm to test a workflow solution for urine cytology.
  • "...an AI-powered computational platform will save time, improve accuracy, and greatly aid research..."
    AIxMed's experience in cytology software and analysis, combined with CorePlus' experience in integrating digital and AI solutions into their day-to-day pathology workflow will come together to provide an end-to-end solution for research-use only urine cytology analysis.
  • "Both AIxMed and CorePlus have demonstrated our commitment to enhancing urine cytology workflow efficiencies utilizing the tools of digital cytology, so joining forces to demonstrate a new digital urine cytology platform together is a natural fit," said Samuel Chen, CEO of AIxMed.
  • Due to the shortage of cytologists and the manual nature of cell characterization, cytology needs new tools to improve workflow and provide quantitative and qualitative information.